JPMorgan Chase & Co. set a €70.00 ($81.40) price objective on Bayer (FRA:BAYN) in a research report report published on Wednesday. The brokerage currently has a neutral rating on the healthcare company’s stock.
BAYN has been the subject of several other reports. Sanford C. Bernstein set a €86.00 ($100.00) target price on Bayer and gave the stock a buy rating in a research report on Wednesday. UBS Group set a €110.00 ($127.91) price target on Bayer and gave the stock a buy rating in a report on Tuesday, January 8th. Nord/LB set a €72.00 ($83.72) price target on Bayer and gave the stock a neutral rating in a report on Wednesday, February 27th. Commerzbank set a €99.00 ($115.12) price target on Bayer and gave the stock a buy rating in a report on Tuesday, November 27th. Finally, Barclays set a €90.00 ($104.65) price target on Bayer and gave the stock a buy rating in a report on Wednesday, November 28th. Nine equities research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company. The company currently has an average rating of Buy and an average target price of €87.83 ($102.12).
Shares of FRA:BAYN opened at €59.30 ($68.95) on Wednesday. Bayer has a 12-month low of €91.58 ($106.49) and a 12-month high of €123.82 ($143.98).
Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, Crop Science, and Animal Health segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.
Featured Article: What are no-load funds?
Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with MarketBeat.com's FREE daily email newsletter.